FLG and neoplasm: Based on our preliminary study, ORs can certainly not yet be considered skin dysfunction markers that are powerful enough to replace already known markers such as filaggrin and involucrin, but ORs might be used in combination with known biomarkers in order to enhance the sensitivity of diagnosis of barrier dysfunction, or to predict if the subject would show skin barrier abnormalities in the future.